Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia

The authors aim to address the complexities of managing relapsed or refractory chronic lymphocytic leukemia (RR CLL/SLL) in the context of evolving therapeutic options, particularly in light of targeted agents like covalent Bruton tyrosine kinase inhibitors and venetoclax-based regimens. They emphasize the importance of personalized treatment strategies that consider various factors such as prior therapies, disease biology, and patient preferences, while also highlighting the potential of emerging therapies to improve outcomes.